Neuren Pharmaceuticals Ltd
ASX:NEU

Watchlist Manager
Neuren Pharmaceuticals Ltd Logo
Neuren Pharmaceuticals Ltd
ASX:NEU
Watchlist
Price: 12.2 AUD -0.08% Market Closed
Market Cap: 1.6B AUD
Have any thoughts about
Neuren Pharmaceuticals Ltd?
Write Note

Neuren Pharmaceuticals Ltd
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Neuren Pharmaceuticals Ltd
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Neuren Pharmaceuticals Ltd
ASX:NEU
EPS (Diluted)
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Recce Pharmaceuticals Ltd
ASX:RCE
EPS (Diluted)
AU$0
CAGR 3-Years
-4%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
EPS (Diluted)
-AU$2
CAGR 3-Years
6%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Botanix Pharmaceuticals Ltd
ASX:BOT
EPS (Diluted)
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
13%
CAGR 10-Years
7%
Probiotec Ltd
ASX:PBP
EPS (Diluted)
AU$0
CAGR 3-Years
26%
CAGR 5-Years
-15%
CAGR 10-Years
10%
Arovella Therapeutics Ltd
ASX:ALA
EPS (Diluted)
AU$0
CAGR 3-Years
21%
CAGR 5-Years
32%
CAGR 10-Years
N/A
No Stocks Found

Neuren Pharmaceuticals Ltd
Glance View

Market Cap
1.6B AUD
Industry
Pharmaceuticals

Founded in 1993, Neuren Pharmaceuticals Ltd has carved a niche for itself within the biotech industry, focusing primarily on neurological and neurodevelopmental disorders. The company operates at the intriguing intersection of innovation and medicine, where the stakes are high, but so are the potential rewards. Neuren has its headquarters in Australia and has oriented its research towards developing therapies that could change the lives of those affected by conditions like Rett syndrome and Fragile X syndrome. By adopting a strategic approach that combines cutting-edge science with a relentless focus on unmet needs, Neuren positions itself uniquely through its proprietary compounds such as trofinetide and NNZ-2591, which are at the core of its research endeavors. The company's business model hinges on a dual approach: developing its own drugs while simultaneously fostering partnerships with larger pharmaceutical companies to bring these therapies to market. This model allows Neuren to share the substantial costs and risks inherent in drug development while benefiting from the expanse of its partners' distribution networks and market insights. Revenue generation kicks in primarily through milestone payments, royalties, and licensing agreements as these partners help navigate the rigorous phases of clinical trials and regulatory approvals. Financial stability is thus intricately tied to clinical successes and strategic alliances, allowing Neuren to balance the speculative nature of biotech investments with the promise of transformative medical breakthroughs.

NEU Intrinsic Value
6.92 AUD
Overvaluation 43%
Intrinsic Value
Price

See Also

What is Neuren Pharmaceuticals Ltd's EPS (Diluted)?
EPS (Diluted)
0.9 AUD

Based on the financial report for Jun 30, 2024, Neuren Pharmaceuticals Ltd's EPS (Diluted) amounts to 0.9 AUD.

What is Neuren Pharmaceuticals Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 1Y
114%

Over the last year, the EPS (Diluted) growth was 114%.

Back to Top